XL 281

Drug Profile

XL 281

Alternative Names: BMS-908662; XL-281

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma

Most Recent Events

  • 11 Jun 2013 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma in USA (NCT01245556)
  • 31 Oct 2011 XL 281 is no longer licensed to Bristol-Myers Squibb
  • 29 Sep 2011 Bristol-Myers Squibb completes a phase I/II trial in Colorectal cancer (metastatic disease, in combination with cetuximab) in US and Canada (NCT01086267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top